La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Journey Medical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Journey Medical..

Journey Medical (NASDAQ:DERM) Azioni, Catena delle Opzioni

Journey Medical

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

wall street chart shutter2

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ALMS

CMRX

DERM

Analisi dei segnali di allarme nel settore sanitario: cosa rivela l&#39;indicatore tecnico chiave per gli investitori. È il momento di agire?

3 titoli del settore sanitario che potrebbero crollare nel secondo trimestre

Journey Medical Corporation - Common Stock

Journey Medical Corp

DermTech Inc

DermTech Inc Warrants(20/06/2022)

Dermapharm Holding SE

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics Inc

Dermisonics Inc

WIIM

Journey Medical shares are trading higher after the company reported better-than-expected Q1 financial results.

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25 percent. This is a 66.04 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $13.14 million which beat the analyst consensus estimate of $12.05 million by 9.00 percent. This is a 0.84 percent increase over sales of $13.03 million the same period last year.

Earnings

Earnings Beats

Journey Medical Q1 EPS $(0.18) Beats $(0.24) Estimate, Sales $13.14M Beat $12.05M Estimate

ADCT

AEVA

AFCG

ALUR

ARCO

ATER

AYTU

BCDA

BITF

BNGO

The Beachbody Company, Inc. Class A Common Stock

BODI

BOOT

BRTX

BZAI

CAAS

CANG

CCAP

CDXS

CELC

CLBT

CLSD

CREX

CSCO

CSPI

CSWC

CTSO

DAVA

DRIO

DYAI

EGAN

ELVA

EPSN

EWCZ

FIHL

FOSL

GCTS

GLBE

GROV

GWRS

HWKN

IBTA

ICCC

INVZ

IREN

ISSC

ITRG

JACK

KARO

KITT

KMDA

KRNT

LAZR

LDTC

LIEN

LIQT

LOCL

LUCD

LUXE

LVLU

MDXH

MGRM

MMYT

NEXN

NSYS

NTWK

NVGS

NYXH

ONCY

PDSB

PYPD

RCAT

RDCM

REKR

RELI

RSKD

SBLK

SCPH

SDHC

SDOT

SDST

SGML

SHIM

Earnings Scheduled For May 14, 2025

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Alumis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>)</h3>
<ul>
<li>On March 25, Alumis, Inc announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals. Under the agreement, Alumis is licensing ESK-001, a drug aimed at treating immune dysregulation in various diseases, to Kaken for development, manufacturing and commercialization in Japan, limited to dermatologic applications.. The company's stock gained around 106% over the past month and has a 52-week high of $13.50.</li>
<li>RSI Value: 77.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ALMS Price Action: Shares of Alumis gained 17.7% to close at $10.05 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Chimerix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>)</h3>
<ul>
<li>On March 21, Chimerix reported quarterly losses of 25 cents per share which beat the analyst consensus estimate of a loss of 26 cents per share. The company reported quarterly sales of $57.00 thousand which missed the analyst consensus estimate of $75.00 thousand by 24.00 percent. The company's stock gained around 837% over the past six months and <a href="https://www.benzinga.com/quote/CMRX">has a 52-week high</a> of $8.54.</li>
<li>RSI Value: 82.7</li>
<li>CMRX Price Action: Shares of Chimerix closed at $8.53 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Journey Medical Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>)</h3>
<ul>
<li>On April 1, Journey Medical Corporation named Ramsey Alloush as Chief Operating Officer. Claude Maraoui, President and Chief Executive Officer of Journey Medical, said, &#8220;Ramsey&#8217;s promotion to COO reflects his exceptional leadership and the critical role he has played in our Company&#8217;s growth. His deep understanding of our business and the industry uniquely positions him to drive our strategic initiatives forward, focusing on operational excellence and maximizing shareholder value.&#8221; The company's stock gained around 40% over the past month and has a 5<a href="https://www.benzinga.com/quote/DERM">2-week high</a> of $7.29.</li>
<li>RSI Value: 77.3</li>
<li>DERM Price Action: Shares of Journey Medical gained 9.1% to close at $7.19 on Friday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Top 3 Health Care Stocks That May Crash In Q2

Alloush Will Continue To Also Serve As The Company's General Counsel.

Management

Journey Medical Promotes Ramsey Alloush, Currently General Counsel, To The Position Of COO

<h3>Companies Reporting Before The Bell</h3>
• Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) is estimated to report quarterly loss at $5.00 per share on revenue of $5.60 million. 
• Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) is projected to report quarterly earnings at $2.18 per share on revenue of $8.23 billion. 
• Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $3.20 billion. 
• Titan America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTAM#NYSE">TTAM</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $384.72 million. 
• Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is likely to report quarterly earnings at $1.06 per share on revenue of $2.60 billion. 
• SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) is expected to report quarterly loss at $0.03 per share on revenue of $202.71 million. 
• REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $152.00 million. 
• CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $358 thousand. 
• Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $80.10 million. 
• JinkoSolar Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) is estimated to report quarterly loss at $0.46 per share on revenue of $3.59 billion. 
• BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is expected to report quarterly earnings at $0.62 per share on revenue of $1.35 billion. 
• Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $88.50 million. 
• Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) is expected to report quarterly loss at $2.94 per share on revenue of $4.28 million. 
• Cheetah Mobile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) is expected to report earnings for its fourth quarter. 
• Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) is projected to report quarterly earnings at $1.48 per share on revenue of $1.51 billion. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Snail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) is estimated to report earnings for its fourth quarter. 
• Integra Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#AMEX">ITRG</a>) is likely to report earnings for its fourth quarter. 
• TAT Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) is likely to report earnings for its fourth quarter. 
• Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $40.63 million. 
• 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) is projected to report quarterly loss at $0.11 per share on revenue of $114.96 million. 
• BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) is projected to report quarterly loss at $0.87 per share on revenue of $20 thousand. 
• Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) is projected to report earnings for its fourth quarter. 
• Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $6.91 million. 
• Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $14.21 million. 
• Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) is expected to report earnings for its fourth quarter. 
• FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $33.09 million. 
• Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is projected to report quarterly earnings at $1.13 per share on revenue of $1.97 billion. 
• Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $2.10 million. 
• H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $797.68 million. 
• Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is expected to report quarterly loss at $0.06 per share on revenue of $1.35 million. 
• Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $21.40 million. 
• Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) is estimated to report quarterly earnings at $1.27 per share on revenue of $276.82 million. 
• Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $3.01 per share on revenue of $2.47 billion. 
• Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is projected to report earnings for its fourth quarter. 
• Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $790.90 million. 
• Guardian Pharmacy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $320.52 million. 
• Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) is expected to report quarterly loss at $0.26 per share on revenue of $232 thousand. 
• MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $918.88 million. 
• Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $87.50 million. 
• Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) is estimated to report earnings for its Fiscal Year 2024. 
• Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $1.56 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALVO

CATX

CHWY

CLGN

CMCM

CNXC

CTAS

DLTR

DOOO

DRRX

DTIL

GRDN

MLKN

MVIS

OXBR

PAYX

SAIL

SNAL

Spruce Power Holding Corporation Class A Common Stock

SPRU

TATT

TTAM

USIO

VRNT

WOOF

ZEPP

Earnings Scheduled For March 26, 2025

DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when administered once daily for 16 weeks
Published data from two Phase 3 clinical trials demonstrated statistical superiority of DFD-29 over both Oracea&#xAE;&nbsp;(doxycycline) capsules and placebo for IGA treatment success and the reduction of total lesion count, as well as significantly superior reduction in erythema compared to placebo in both studies
U.S. FDA approved Emrosi&#x2122; (also known as DFD-29) for the treatment of inflammatory lesions of rosacea in adults in November 2024; launch expected in early spring of 2025
SCOTTSDALE, Ariz., March 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that full results from two Phase 3 multicenter, randomized, double-blind, parallel-group, active-comparator and placebo-controlled clinical trials, Minocycline Versus Oracea&#xAE; in Rosacea-1 ("MVOR-1") and Minocycline Versus Oracea in Rosacea-2 ("MVOR-2"), evaluating Minocycline Hydrochloride Extended Release Capsules, 40 mg ("DFD-29" or "Emrosi") for the treatment of moderate-to-severe papulopustular rosacea in adults were published in the Journal of the American Medical Association - Dermatology ("JAMA Dermatology"). The results demonstrated the efficacy, safety and tolerability of oral DFD-29 in rosacea. Read the full publication here: <a href="https://www.globenewswire.com/Tracker?data=IQdcOCvkQy_om0z2ylvmrLZvuKwN_lqXU9gCO2NkphJvMndfr31QK9hYRaVC98MD9ELN95UcKRHs-hFxotfbcpH8nTC5_WhywP2ePZ6su2vfm6DEAD7h6POklP8XJYbe4t2Pdtb_s_QZf9Tq3Iau4Q==">JAMA</a>.
The FDA approved Emrosi&#x2122; for the treatment of inflammatory lesions of rosacea in adults in November 2024.

Biotech

General

Journey Medical Announces Publication In The Journal Of The American Medical Association - Dermatology Of The Phase 3 Clinical Trial Results Of Emrosi To Treat Rosacea; DFD-29 Achieved The Co-Primary And All Secondary Endpoints With No Significant Safety Issues When Administered Once Daily For 16 Weeks

<h3>Gainers</h3>
<ul>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) shares rose 26.9% to $3.82 during Friday's pre-market session. The market value of their outstanding shares is at $186.6 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock increased by 19.74% to $0.39. The market value of their outstanding shares is at $6.4 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock rose 17.01% to $0.78. The company's market cap stands at $48.1 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock rose 14.44% to $1.03. The market value of their outstanding shares is at $4.6 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock increased by 12.84% to $1.23. The market value of their outstanding shares is at $10.7 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) shares rose 11.76% to $0.95. The company's market cap stands at $62.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) stock fell 74.5% to $2.19 during Friday's pre-market session. The market value of their outstanding shares is at $254.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock declined by 13.52% to $4.8. The market value of their outstanding shares is at $100.2 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined by 12.64% to $7.05. The company's market cap stands at $4.7 billion. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock fell 12.38% to $4.25. The company's market cap stands at $47.1 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock declined by 10.37% to $0.54. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 9.96% to $1.9. The company's market cap stands at $191.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APLT

ARAY

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BMRA

CABA

GRFS

IOBT

NTRB

PASG

SILO

TCBP

12 Health Care Stocks Moving In Friday's Pre-Market Session

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 115 percent decrease over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $14.63 million which beat the analyst consensus estimate of $14.39 million by 1.68 percent. This is a 57.64 percent decrease over sales of $34.54 million the same period last year.

Journey Medical Q3 EPS $(0.12) Beats $(0.15) Estimate, Sales $14.63M Beat $14.39M Estimate

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 127.9% to $3.1 during Monday's regular session. The company's market cap stands at $5.7 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) stock moved upwards by 58.24% to $21.3. The company's market cap stands at $53.1 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares increased by 44.04% to $66.36. The market value of their outstanding shares is at $862.2 million. </li>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) stock rose 24.27% to $23.96. The company's market cap stands at $1.8 billion. As per the press release, Q3 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 23.42% to $1.37. The market value of their outstanding shares is at $22.3 million. </li>
<li>Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) shares moved upwards by 22.19% to $57.59. The market value of their outstanding shares is at $1.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares decreased by 15.8% to $1.98 during Monday's regular session. The company's market cap stands at $10.7 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) stock declined by 15.6% to $7.12. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares declined by 15.57% to $12.1. The market value of their outstanding shares is at $497.2 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares decreased by 15.52% to $14.87. The market value of their outstanding shares is at $22.2 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 13.5% to $2.05. The company's market cap stands at $349.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock decreased by 13.3% to $5.35. The market value of their outstanding shares is at $110.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCRX

BSGM

CVKD

IART

IRON

NGNE

NUWE

OMIC

THRD

TVGN

XTLB

12 Health Care Stocks Moving In Monday's Intraday Session

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the <a href="https://www.benzinga.com/pressreleases/24/11/g41709594/journey-medical-corporation-announces-u-s-fda-approval-of-emrosi-minocycline-hydrochloride-extende">treatment of rosacea</a>.
What Happened: The FDA has approved Journey Medical&#8217;s Emrosi, formerly known as DFD-29, for the treatment of inflammatory lesions of rosacea in adults.&nbsp;
The approval was supported by positive data from the company&#8217;s two Phase 3 clinical trials, which met all co-primary and secondary endpoints. Journey Medical said Emrosi demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea, and placebo. 
Journey Medical announced that it&#8217;s in the process of completing the manufacturing of Emrosi for the U.S. market. The company expects initial supply of the drug to be available late in the&nbsp;first quarter&nbsp;or early in the&nbsp;second quarter&nbsp;of 2025.
&#8220;With approval from the FDA, Journey Medical is proud to deliver Emrosi, a unique treatment option for the millions of patients in the U.S. suffering from rosacea,&#8221; said Claude Maraoui, co-founder, president and CEO of Journey Medical.
&#8220;Rosacea is a difficult to treat skin condition and based on the favorable results from our Phase 3 clinical trials, Emrosi has potential to become the best-in-class oral medication to treat the condition. Our seasoned dermatology-focused sales force is now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea.&#8221;
Journey Medical said it intends to commercialize Emrosi in the U.S. with its dermatology-focused commercial organization. The company aims to execute a launch strategy to help push Emrosi toward becoming the new oral standard of care for adult rosacea patients.
See Also:<a href="https://www.benzinga.com/general/biotech/24/11/41713478/jim-cramer-says-vertex-doing-lords-work-can-q3-earnings-outshine-bearish-charts"> Jim Cramer Says Vertex Doing &#8216;Lord&#8217;s Work&#8217;: Can Q3 Earnings Outshine Bearish Charts?</a>
DERM Price Action: <a href="http://benzinga.com/quote/derm">Journey Medical shares</a> were up 3.40% at $6.38 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

What's Going On With Journey Medical Stock Today?

Journey Medical shares are trading higher after the company announced the preparation of the U.S. launch of its FDA-approved rosacea drug Emrosi.

Journey Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi&#x2122; (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories Ltd.
Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Journey Medical, said, "With approval from the FDA, Journey Medical is proud to deliver Emrosi, a unique treatment option for the millions of patients in the U.S. suffering from rosacea. Rosacea is a difficult to treat skin condition and based on the favorable results from our Phase 3 clinical trials, Emrosi has potential to become the best-in-class oral medication to treat the condition. Our seasoned dermatology-focused sales force is now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea. Journey Medical is committed to bringing cutting-edge innovation to patients with dermatological conditions and the healthcare professionals who treat them."
The approval of Emrosi is supported by positive data from Journey Medical's two Phase 3 clinical trials for the treatment of rosacea. The Phase 3 clinical trials met all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues. Emrosi demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea&#xAE; 40 mg capsules, and placebo for Investigator's Global Assessment treatment success as well as the reduction in total inflammatory lesion count in both studies.
Journey Medical is completing the manufacturing of Emrosi for the U.S. market and anticipates that initial supply will be available late in the first quarter or early in the second quarter of 2025. Journey Medical intends to commercialize Emrosi in the U.S. with its dermatology-focused commercial organization. In line with the approved label, Journey Medical will execute a launch strategy to drive Emrosi toward becoming a new oral standard of care for adult rosacea patients.
Srinivas Sidgiddi, M.D., Vice President, Research &amp; Development at Journey Medical, added, "Emrosi showed great efficacy and tolerability in the pivotal clinical trials, and we are tremendously grateful to the patients, physicians, investigators, and site coordinators who participated and contributed to this important approval milestone."

Government

Regulations

Journey Medical Prepares US Launch for FDA-Approved Rosacea Drug Emrosi

Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea&#xAE;) in Healthy Subjects
With its modified-release formulation, DFD-29 (40 mg) provides higher dermal concentration than doxycycline from Day 1 onward at a similar dose, expected to translate into a clinically meaningful impact for treating patients with rosacea
New Drug Application for DFD-29 under review by FDA with PDUFA goal date of November 4, 2024

Events

Journey Medical Presents DFD-29 Data At 44th Fall Clinical Dermatology Conference

Lake Street analyst Thomas Flaten initiates coverage on Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) with a Buy rating and announces Price Target of $9.

Price Target

Initiation

Analyst Ratings

Lake Street Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9

Rodman &amp; Renshaw initiates coverage on Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) with a Buy rating and announces Price Target of $9.

Rodman & Renshaw Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9

Journey Medical shares are trading higher after the company reported better-than-expected Q2 revenue results.

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 63.04 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $14.855 million which beat the analyst consensus estimate of $13.880 million by 7.02 percent. This is a 13.49 percent decrease over sales of $17.172 million the same period last year.

Earnings Misses

Journey Medical Q2 2024 GAAP EPS $(0.17) Misses $(0.14) Estimate, Sales $14.855M Beat $13.880M Estimate

Comments

Journey Medical

Journey Medical (DERM) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO